ORIGINAL RESEARCH article
Front. Public Health
Sec. Public Health Policy
This article is part of the Research TopicAdvancing Oncology Drug Development, Approval and Access Through Multi-Stakeholder CollaborationView all 7 articles
Effect of the National Reimbursement Drug List Negotiation Policy on utilization of negotiated Anticancer Drugs in Chinese Public Hospital: A Quasi-Natural Experiment
Provisionally accepted
- 1Second Affiliated Hospital of Heilongjiang Chinese Medicine University, Harbin, China
- 2Harbin Medical University, Harbin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background High prices have limited access to targeted anticancer drugs in China. In 2017, 18 such drugs were added to the National Reimbursement Drug List (NRDL) through national price negotiation. Methods Monthly hospital procurement data (2015–2019) from 887 public hospitals across 30 provinces were analyzed. Drug utilization was measured by expenditures and defined daily doses (DDDs). A difference-in-differences (DID) model and interrupted time series (ITS) analysis were employed to estimate policy effects. Results Following policy implementation, total DDDs of negotiated drugs rose 4.03-fold and expenditures 3.07-fold, both exceeding cancer incidence growth. DID analysis confirmed significant increases for Western medicines (+479,100 DDDs; p < 0.001). ITS showed sustained upward trends, especially for Trastuzumab, Bevacizumab, and Abiraterone, while traditional Chinese medicines declined. Bevacizumab demonstrated improved affordability, with higher DDDs but lower expenditures. Conclusion The NRDL negotiation substantially improved access to targeted anticancer therapies in public hospitals while containing cost growth. These findings highlight the effectiveness of centralized price negotiation in expanding coverage and equity of high-cost cancer treatments in resource-constrained settings.
Keywords: anticancer drug, national reimbursement drug list negotiation, Drug Utilization, Policy evaluation, China
Received: 09 Jul 2025; Accepted: 06 Nov 2025.
Copyright: © 2025 Liu, Li, Sun, Liu, Zhang, Wang, Yanping, Qunhong and Shan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wu Qunhong, wuqunhong@163.com
Linghan Shan, linghanshan@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.